Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21640265 | 0.86 | NR1H2 (0.54) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL22680124 | 0.85 | HPGD (0.50) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL31319964 | 0.85 | HPGD (0.50) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL23207055 | 0.85 | HPGD (0.50) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL24683190 | 0.83 | MEN1 (0.53) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL20635761 | 0.82 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL26049286 | 0.82 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL16759817 | 0.81 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL15764146 | 0.81 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL15764147 | 0.81 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137984-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024008048-A1 | NOVEL PYRIMIDINE OR TRIAZINE-SUBSTITUTED PYRIDOHETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2024-01-11 | — | — | WO | disclosed |
| US-20220117945-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-21 | — | — | US | disclosed |
| US-20220117945-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-21 | — | — | US | disclosed |
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-110461835-A | Isoxazole benzamide compound and application thereof | NOVARTIS AG | 2019-11-15 | — | — | CN | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | NR1H2 895/4885USP2 2336/4885SMN1; SMN2 1918/4885 |
| US-20220117945-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | SLC26A4, SLC26A3, ALDH5A1 | NR1H2 2621/4885USP2 4363/4885SMN1; SMN2 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.